Dr James Tysome
Position: Clinical Consultant
Personal home page:
http://www.cuh.org.uk/addenbrookes/services/clinical/skull_base_unit/skull_base_index.html
PubMed journal articles - click here
Dr James Tysome is pleased to consider applications from prospective PhD students.
Angiogenesis plays a role in the growth of many skull base and head and neck tumours. I aim to investigate the role of angiogenesis inhibitors in these tumours, develop novel inhibitors including oncolytic viruses and use molecular imaging techniques to determine tumour growth rates and response to treatment. I am also interested in the use of hearing implants in patients with neurofibromatosis type 2.
Symplectic Elements feed provided by Research Information, University of Cambridge
Tysome JR, Li X, Wang S, Wang P, Gao P, Du P, Chen D, Gangeswaran R, Chard L, Yuan M, Alusi G, Lemoine NR. A novel therapeutic regime to eradicate established solid tumors with an effective induction of tumor-specific immunity (2012). Clinical Cancer Research 18(24):6679-89 Tysome JR, Macfarlane R, Durie-Gair J, Donnelly N, Mannion R, Knight R, Harris F, Vanat ZH, Tam YC, Burton K, Hensiek A, Raymond FL, Moffat DA, Axon PR. Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2 (2012). Otology Neurotology 33(3):466-72 Tysome JR, Wang P, Briat A, Alusi G, Gangeswaran R, Bhakta V, Francis J, Timiryasova T, Fodor I, Lemoine NR, Wang Y. Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: a superior oncolytic virus to dl1520 (ONYX-015) for human head and neck cancer (2011). Human Gene Therapy 22(9):1101-8
